Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom
Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom
复制标题
DOI：
10.1177/147323001003800102
复制
发表时间：
2010-01-01
影响因子：
1.6
通讯作者：
de la Orden, M.
中科院分区：
文献类型：
--
作者：
Lewis, G.;Peake, M.;de la Orden, M.
这项研究旨在评估厄洛替尼与多西紫杉醇在英国国家医疗服务体系(NHS)内治疗晚期非小细胞肺癌(NSCLC)二线治疗中的成本效益。基于厄洛替尼或多西紫杉醇与最佳支持性治疗的两项随机第三阶段研究的健康-状态转换模型被用来估计总的直接成本、质量调整的寿命年(QALY)和随后的净货币收益。与多西紫杉醇相比，厄洛替尼与总成本(13730磅比13磅956)的降低和结果的改善(总的QALY分别为0.238比0.206)有关。敏感度分析证明了该分析的稳健性。总而言之，与多西紫杉醇相比，厄洛替尼似乎产生了类似的总体存活率，QALY增加，NHS总成本略有降低，这是因为不良事件和药物管理成本更低。因此，从卫生经济学的角度来看，在英国治疗复发的III-IV期NSCLC患者时，厄洛替尼比多西紫杉醇具有优势。
This study was designed to assess the cost-effectiveness of erlotinib compared with docetaxel in the second-line management of advanced non-small-cell lung cancer (NSCLC) within the UK National Health Service (NHS). A health-state transition model, based on two randomized phase III studies of erlotinib or docetaxel versus best supportive care, was used to estimate total direct costs, quality-adjusted life years (QALYs) and the subsequent net monetary benefit. Erlotinib was associated with a reduction in total costs (13730 pound versus 13 pound 956) and improved outcomes (total QALYs of 0.238 versus 0.206) compared with docetaxel. Sensitivity analyses demonstrated the robustness of this analysis. In summary, erlotinib appeared to generate similar overall survival, an increase in QALYs and a small reduction in total NHS costs compared with docetaxel, due to lower adverse event and drug administration costs. Consequently, from a health economics perspective for the treatment of relapsed stage III - IV NSCLC patients in the UK, erlotinib has advantages over docetaxel.